Microalbumin/Creatinine Ratio
An early-warning screen for kidney damage — the same test as uACR.
Medically reviewed by Dr. Rishi Kumar Kafle, MBBS, MD, FASN · Last reviewed June 2026
The microalbumin/creatinine ratio detects small amounts of albumin in the urine to screen for early kidney damage — often before standard tests turn abnormal. It is the same measurement as the urine albumin-to-creatinine ratio (uACR); the “micro” refers to the small quantities being measured, not a different test. A normal result is under 30 mg/g.
What “Microalbumin” Actually Means
A routine urine dipstick only flags protein once a fair amount is leaking. “Microalbumin” testing is far more sensitive: it picks up the small quantities of albumin that escape when kidney damage is just beginning. The word is a little misleading — it is not a special small kind of albumin, just ordinary albumin measured at low concentrations the standard dipstick would miss. Dividing the albumin by urine creatinine corrects for dilution, so a single random spot sample gives a dependable number without a 24-hour collection.
How It Maps to KDIGO
The older term microalbuminuria corresponds to the KDIGO A2 category. The modern guidelines retired the micro/macro labels in favor of three numbered bands:
| uACR (mg/g) | KDIGO category | Older term |
|---|---|---|
| < 30 | A1 — normal to mildly increased | Normoalbuminuria |
| 30–300 | A2 — moderately increased | Microalbuminuria |
| > 300 | A3 — severely increased | Macroalbuminuria |
So a result of 45 mg/g is microalbuminuria (A2); 15 mg/g is normal (A1); and 350 mg/g has crossed into A3. Read the full grading on the albumin/creatinine ratio page.
Why It Is Done
It is a key screening test in diabetes and high blood pressure, where early, treatable kidney damage often shows up first as a small rise in albumin — usually well before eGFR falls. Catching the A2 stage early opens a window for treatments that can slow, and sometimes reverse, the leak. Guidelines suggest annual screening for people with diabetes and confirming any abnormal result with a repeat sample.
Why Diabetes Makes This Test Routine
Diabetes is the leading cause of kidney failure worldwide, and the damage usually announces itself first as a small albumin leak — long before symptoms or a drop in filtration. That is why people with type 2 diabetes are typically screened with a microalbumin/creatinine ratio at diagnosis and then yearly, and those with type 1 diabetes starting about five years after diagnosis. Catching the move from A1 into A2 gives the best chance to intervene while the kidney can still recover. The same early-warning logic applies in long-standing high blood pressure, where a rising ratio signals strain on the kidney's filtering vessels.
How the Sample Is Taken
A first-morning urine sample is preferred because albumin output is lowest and most stable after a night lying down, avoiding the rise that upright posture and daytime activity can cause. A random spot sample works when morning collection is not practical. In every case the lab measures both albumin and creatinine from the same specimen and divides, so the result corrects for urine dilution without any timed collection. This simplicity is exactly what makes annual screening feasible.
Examples Across the Range
Three readings show how the test plays out. A person with diabetes returning 18 mg/g is in the normal A1 band and continues routine yearly screening. A repeat value of 90 mg/g, confirmed on a second sample, sits in A2 (microalbuminuria) and typically prompts a kidney-protective medication and tighter blood pressure and sugar control. A value of 320 mg/g has crossed into A3, indicating heavier, more advanced leakage that warrants closer specialist follow-up. The pattern over time matters more than any single figure.
Confirming a Positive Result
A single raised microalbumin reading is not enough to diagnose kidney disease. Strenuous exercise, fever, urinary infection, and short-term blood sugar spikes can all push albumin up temporarily. A persistent elevation across two of three samples over three to six months is what defines true albuminuria. A falling ratio on repeat testing, by contrast, suggests treatment is working. Interpret the trend, alongside eGFR and blood pressure, with a clinician rather than acting on one number.
Why “Micro” and “Macro” Fell Out of Use
The older labels — normo-, micro-, and macroalbuminuria — implied three sharply separate states, when in reality albumin loss runs along a continuous spectrum of risk. KDIGO replaced them with the A1, A2, and A3 categories to emphasize that risk rises smoothly as the ratio climbs, and that the boundaries are convenient markers rather than biological cliffs. The word “microalbumin” survives on many lab reports and in everyday conversation, so it helps to know that it simply means the A2 range of 30–300 mg/g on the modern scale.
What Happens After a Confirmed Result
Once albuminuria is confirmed, the ratio becomes a tool for guiding and monitoring treatment rather than just detection. Blood pressure control, blood sugar management in diabetes, and specific kidney-protective medications can all lower the ratio, and repeat testing shows whether they are working. The number is therefore read in two ways over time: as an early warning at first, and then as a feedback signal on therapy. Always interpret it alongside eGFR and the broader clinical picture with a clinician.
A More Sensitive Test Than the Dipstick
It is worth being clear about why a dedicated microalbumin test exists at all. A standard urine dipstick only turns positive once protein loss is fairly heavy, so it routinely misses the small albumin leak of early kidney damage. The microalbumin/creatinine ratio is far more sensitive, detecting concentrations the dipstick cannot see. That sensitivity is exactly what makes it valuable as a screening tool in people who feel completely well but carry a high risk of kidney disease, such as those with diabetes or high blood pressure.